Laurus Labs (LAURUSLABS.NS) Stock Price
Laurus Labs Price
Revenue has compounded at 18.9% per year over the past 13 years to 68.13 B INR. Earnings per share have grown at 19.4% per year over the last 13 years. Laurus Labs's net margin stands at 13.0%, down from 16.8% several years earlier. Laurus Labs currently offers a dividend yield of about 0.08%. The payout ratio is around 21% of earnings. The dividend has grown at 20.4% per year over the past 9 years. Analysts set a median price target of 1,060.80 INR, implying 48.1% below the current price. Of 20 analysts, 5 rate the stock a buy — an overall Sell consensus.
Laurus Labs stock price
Laurus Labs business model & stock analysis
Frequently asked questions about Laurus Labs
Laurus Labs Ltd is primarily present in various countries and regions across the globe. The company has established a significant presence in India, where its headquarters are located. In addition, Laurus Labs Ltd has a strong presence in the United States, Europe, and other key markets. With its comprehensive global reach, the company is able to cater to a diverse customer base and leverage its international operations for growth and market expansion.
The business model of Laurus Labs Ltd is centered around the development, manufacturing, and marketing of generic active pharmaceutical ingredients (APIs) and formulations. Laurus Labs specializes in offering cost-effective and high-quality healthcare solutions, serving both domestic and international markets. The company operates across various segments such as APIs, generic formulations, synthesis and nutraceuticals. Laurus Labs focuses on innovation, research and development, and maintaining strong customer relationships to drive growth and expansion in the pharmaceutical industry. With its expertise in the production of APIs and formulations, Laurus Labs aims to provide affordable healthcare solutions, contributing to the betterment of global health.
Laurus Labs Ltd is primarily active in the pharmaceutical industry.
The main competitors of Laurus Labs Ltd in the market include generic pharmaceutical companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla Limited, Lupin Limited, and Aurobindo Pharma. These companies also specialize in the production and distribution of generic drugs, actively competing with Laurus Labs in terms of product offerings, pricing, and market share.
Laurus Labs Ltd, founded in 2005, is a leading research-driven pharmaceutical company based in Hyderabad, India. With a focus on developing and manufacturing high-quality generic Active Pharmaceutical Ingredients (APIs) and finished dosage forms, Laurus Labs has emerged as a global leader in the healthcare industry. The company's strong commitment to innovation, quality, and sustainability has facilitated its growth into a diversified and vertically integrated organization. Laurus Labs caters to diverse therapeutic areas such as antiretrovirals (ARVs), oncology, hepatitis C, and other chronic diseases. Through strategic partnerships, state-of-the-art infrastructure, and a diligent team, Laurus Labs continues to deliver transformative healthcare solutions worldwide.
Laurus Labs Ltd, a leading pharmaceutical company, has achieved significant milestones over the years. One notable achievement is its successful listing on the stock exchanges in 2016, marking a significant step in its growth trajectory. The company's robust expansion plans and strategic acquisitions have further strengthened its position in the industry. Laurus Labs Ltd has also received several prestigious certifications, including the USFDA approval for its manufacturing facilities, showcasing its commitment to quality and compliance. The company's consistent revenue growth and strong financial performance have earned it recognition as one of the fastest-growing pharmaceutical companies in India.
Laurus Labs Ltd represents strong values and a robust corporate philosophy. The company focuses on delivering high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). Laurus Labs promotes integrity, innovation, and sustainability throughout its operations. With a customer-centric approach, the company strives to provide affordable healthcare solutions globally. Laurus Labs aims to enhance access to affordable medicines while adhering to stringent quality standards. Through continuous research and development, Laurus Labs aims to develop innovative products that cater to the evolving needs of the pharmaceutical industry. The company's commitment to excellence and continuous improvement defines its corporate philosophy.
Analysts currently set an average price target of 1,014.43 INR for the Laurus Labs stock (median: 1,060.80 INR), implying -50.4 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Laurus Labs stock: 5 recommend buying, 5 holding and 10 selling.
Converted at the current exchange rate, the Laurus Labs share trades at 18.88 EUR (2,044.10 INR).
The Laurus Labs share (LAURUSLABS.NS) is listed on 2 stock exchanges, including: NSE (Indien) (LAURUSLABS.NS).
Laurus Labs Ltd is a leading pharmaceutical company that delivers innovative solutions for the healthcare industry. The company has been operating in Hyderabad, India since 2005 and currently employs over 6,500 employees. The business model of Laurus Labs consists of three main divisions: generics, active pharmaceutical ingredients (API), and synthesis. The generics division focuses on manufacturing high-quality and affordable generics that are marketed worldwide. The API division produces pharmaceutical raw materials used by global pharmaceutical companies to manufacture their own products. The synthesis division produces intermediate products and specialty chemicals used in various industries such as cosmetics, agrochemicals, and polymer processing industries. Laurus Labs' products include a wide range of generics in various therapy areas such as oncology, HIV, hepatitis C, CNS, and cardiovascular. Some of the company's key medications include Abacavir, Emtricitabine, Dolutegravir, Lopinavir, Ritonavir, and Pregabalin. The company also manufactures over 50 API products including Duloxetine, Rivaroxaban, Apixaban, and Varenicline Tartrate. Laurus Labs has a strong research and development department with 400+ scientists focusing on the research of generics and innovative drugs. The company also has partnerships with several high-profile global pharmaceutical companies such as Pfizer, Aspen, Teva, and Merck. Laurus Labs has a business model focused on quality, agility, and customer orientation. The company has state-of-the-art production facilities validated according to international standards such as FDA, EU-GMP, and TGA. The company has one of the largest capacities for scaling up API products in India. The company also has a professional sales team with a strong presence in North America, Europe, and Asia. The company is also committed to achieving its sustainability goals and minimizing the environmental impact of its activities. The company has taken measures to improve energy efficiency, waste reduction, and wastewater treatment. In summary, Laurus Labs' business model is focused on a highly diversified production of generics, API, and synthesis products. The company has earned an excellent reputation for quality, agility, and customer orientation and has strong partnerships with global pharmaceutical companies. With a strong research and development department, Laurus Labs aims to continue growing in the pharmaceutical industry and delivering innovative solutions for the healthcare industry.
The revenue of Laurus Labs is 68.13 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Laurus Labs is 8.89 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Laurus Labs is currently 124.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Laurus Labs stock.
The price-to-sales ratio (P/S) of Laurus Labs is currently 16.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Laurus Labs stock.
The Eulerpool Quality Score for Laurus Labs is 5/10.
The ISIN of Laurus Labs is INE947Q01028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Laurus Labs is LAURUSLABS.NS. The ticker symbol is used to trade Laurus Labs shares on the stock exchange.
Laurus Labs stock
Laurus Labs Peer Group
Laurus Labs Ticker
Laurus Labs FIGI
All fundamentals and in-depth analysis of Laurus Labs
Our stock analysis for Laurus Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laurus Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.